Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...
It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
As part of our series looking at how pharma companies have adapted to the pandemic, Shannon Rush, leader of Eli Lilly and ... patents covering mRNA vaccines for COVID-19 and respiratory syncytial ...
Relay Therapeutics Inc. (NASDAQ:RLAY) is a leading clinical-stage precision medicines firm focused on cancer treatments. The ...
Pfizer PFE will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...
In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...
Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...